
    
      Weekly intramuscular injections of 250mg 17-alpha hydroxyprogesterone caproate (17P) or
      indistinguishable placebo will be randomly allocated in a 1:1 ratio started between 16-24
      weeks gestation and administered weekly thereafter until 36 6/7 gestational weeks,
      stillbirth, or delivery, whichever is sooner.

      Individual participants will be followed from enrollment (prior to 24 weeks gestation)
      through 42 days postpartum.
    
  